AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3300
+0.0200 (+1.53%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.3100
Open1.3100
Bid1.3200 x 4000
Ask1.3600 x 28000
Day's Range1.2700 - 1.3454
52 Week Range1.1900 - 5.4600
Volume1,921,840
Avg. Volume2,447,869
Market Cap167.774M
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 22, 1991
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Akorn Announces Extension of Standstill Agreement

    Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, today announced that Akorn and certain of its lenders have reached an agreement that extends the standstill period to February 7, 2020. Additional information is available on Akorn’s website at www.akorn.com.

  • GlobeNewswire

    Akorn to Present at the Credit Suisse Healthcare Conference

    LAKE FOREST, Ill., Nov. 05, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that management will present at the Credit Suisse.

  • GlobeNewswire

    Akorn Provides Preliminary Third Quarter 2019 Results

    LAKE FOREST, Ill., Oct. 31, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its preliminary financial results for the third.

  • GlobeNewswire

    Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

    LAKE FOREST, Ill., Oct. 14, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire

    Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, October 31, 2019 outlining its third quarter 2019 financial results. In addition, the Company has scheduled a conference call at 10:00 a.m. ET on the same day to discuss its third quarter 2019 financial and operating results. To access the live webcast, please go to Akorn’s Investor Relations website at http://investors.akorn.com.

  • GlobeNewswire

    Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%

    LAKE FOREST, Ill., Aug. 26, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire

    Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its second quarter 2019 financial results. In addition, the Company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss its second quarter 2019 financial results. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

  • GlobeNewswire

    Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. According to IQVIA, U.S. sales of Loteprednol Etabonate Ophthalmic Suspension, 0.5% were approximately $90 million for the twelve months ended April 2019.

  • GlobeNewswire

    Akorn Receives FDA Warning Letter

    Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter.  The Company will respond to the FDA letter within the required 15 working days from receipt of the letter. Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “Akorn is committed to resolving the warning letter in a comprehensive and effective manner.

  • GlobeNewswire

    Akorn to Present at the Jefferies 2019 Global Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at http://investors.akorn.com/events-and-presentations. The webcast may include forward-looking statements about, among other things, the Company’s business plans and initiatives, the Company’s commitments to the FDA and remediation efforts, disruptions during the Standstill Period, the Company’s anticipated future operating and financial performance, business plans and prospects, product pipeline, including filings, approvals and launches, capital allocation, debt refinancing, and potential dispositions, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

  • GlobeNewswire

    Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

    LAKE FOREST, Ill., May 20, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire

    Akorn to Present at the RBC Capital Markets Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY. A live webcast of the presentation can be accessed on the investor page of Akorn's website at http://investors.akorn.com. A replay of the webcast will also be available for 90 days on Akorn's website following the conference.

  • GlobeNewswire

    Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

    -Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 -- Akorn,.

  • Business Wire

    Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)

    Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Illinois, captioned Juan v. Akorn Inc. et al., (Case No. 19-cv-2720), on behalf of persons and entities that purchased or otherwise acquired Akorn, Inc. (NASDAQ: AKRX) (“Akorn” or the “Company”) securities between May 2, 2018 and January 8, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). On January 9, 2019, Akorn announced that it had received a warning letter “dated January 4, from the U.S. Food and Drug Administration (FDA) related to an inspection of its Decatur, Illinois manufacturing facility in April and May of 2018.” The warning letter from the FDA detailed a laundry list of “significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.” On this news, shares of Akorn fell $0.46 per share or over 11.6% to close at $3.48 per share on January 9, 2019, thereby injuring investors.

  • GlobeNewswire

    FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, April 22, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.

  • GlobeNewswire

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX) securities between August 1, 2018 and January 8, 2019, inclusive (the “Class Period”). Akorn investors have until April 22, 2019 to file a lead plaintiff motion in this class action. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

  • GlobeNewswire

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and January 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before April 22, 2019.

  • ACCESSWIRE

    FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • ACCESSWIRE

    3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (''Akorn'' or ''the ...

  • GlobeNewswire

    Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI

    BOSTON, April 19, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important.

  • GlobeNewswire

    Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate Ophthalmic Suspension, 0.5%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.

  • GlobeNewswire

    Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.

  • GlobeNewswire

    APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. – AKRX

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Akorn, Inc. (AKRX) from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akorn investors under the federal securities laws.  If you wish to serve as lead plaintiff, you must move the Court no later than April 22, 2019. To join the Akorn class action, go to http://pawarlawgroup.com/cases/akorn-inc/ or call Vik Pawar, Esq.

  • ACCESSWIRE

    4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (''Akorn'' or ''the ...

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX

    Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (“Akorn” or the “Company”) (AKRX) and certain of its officers and directors.   The class action, filed in United States District Court, Northern District of Illinois, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired publicly traded securities of Akorn from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of federal securities laws (the “Class”).